http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2244870-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5dfc0b033ac4c841466d97a5f28ea32b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12 |
| filingDate | 1997-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_715bf9b52e236d5d66cec00357565b85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdef9d58b9ef056e863573601c9863b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e12efd08d80207e3284d2669173f201 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e3c2810aebc5cc2c2a3535f0f186fb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e32e01285b634a8ebc1787cf8e89ff28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82ed778400e5d64cd17d4d1adc900b21 |
| publicationDate | 1997-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2244870-A1 |
| titleOfInvention | N,n-disubstituted amic acid derivatives |
| abstract | A compound represented by general formula (I) or a pharmaceutically acceptable salt or ester thereof: (see formula I) [wherein each of Ar1, Ar2, Ar3 and Ar4 is an aryl group or an aromatic heterocyclic group; A1 is a C2-6 chain hydrocarbon group or a group represented by -A1a-W1-A1b-(wherein W1 is an oxygen atom, a sulfur atom, an ethynylene group, a cyclopropylene group or a group represented by -NR W-; A2 is a C2-8 chain hydrocarbon group; each of X and Y is an oxygen atom, a sulfur atom, a carbonyl group or a group represented by -CHR a- or by -NR b-, or X and Y together represent a vinylene group or an ethynyl ene group; each of R1, R2, R3, R7 and R8 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group, a lower alkenyl group or a lower alkoxy group; each of R4 and R5 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkyl group, a lower hydroxyalkyl group, a lower fluoroalkyl group or a lower alkoxy group; and R6 is a lower alkyl group, provided that when one of X and Y is an oxygen atom, a sulfur atom or a group represented by -NR b-, the other is a carbonyl group or a group represented by -CHR a- and an antitumor agent comprising it as an active ingredient. |
| priorityDate | 1996-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.